• Skip to primary navigation
  • Skip to main content
  • Skip to footer
ElevateBio

ElevateBio

Powering the creation of cell & gene therapies at a speed the world deserves.

  • Investors & Media
    • Investors & Media Overview
    • Press Releases
    • Posters & Publications
    • Elevated Insights
  • Careers
  • Locations
  • Contact
  • Search
  • End-to-End Capabilities
    • End-to-End Capabilities Overview
    • cGMP Manufacturing and Automation
    • Process Development
    • Analytical Services and Quality
    • Next-Generation Sequencing
    • Apheresis
    • Enabling Services
  • Technology Platforms
    • Technology Platforms Overview
    • Gene Editing
    • Cell Therapy Enabling Technologies
    • RNA, Protein & Vector Engineering
  • Therapeutic Design & Approaches
    • Therapeutic Design & Approaches Overview
    • Ex Vivo Cell & Gene Therapies
    • In Vivo Gene Therapies
  • Partnering
    • Partnering Overview
    • Industry Partnerships
    • Academic Partnerships
  • About
    • About Overview
    • Our Story
    • Our Ecosystem
    • Our Team
    • Culture of Expedition
    • Careers
  • Investors & Media
    • Investors & Media Overview
    • Press Releases
    • Posters & Publications
    • Elevated Insights
  • Careers
  • Locations
  • Contact
  • End-to-End Capabilities


    End-to-End Capabilities Overview

    • cGMP Manufacturing and Automation
    • Process Development
    • Analytical Services and Quality
    • Next-Generation Sequencing
    • Apheresis
    • Enabling Services
  • Technology Platforms


    Technology Platform Overview

    • Gene Editing
    • Cell Therapy Enabling Technologies
    • RNA, Protein & Vector Engineering
  • Therapeutic Design & Approaches


    Therapeutic Design & Approaches Overview

    • Ex Vivo Cell & Gene Therapies
    • In Vivo Gene Therapies
  • Partnering
    • Partnering Overview
    • Industry Partnerships
    • Academic Partnerships
  • About
    • About Overview
    • Our Story
    • Our Ecosystem
    • Our Team
    • Culture of Expedition
    • Careers

Explore
More

  • Apheresis
  • Next-Generation Sequencing
  • cGMP Manufacturing and Automation
  • Process Development
  • Analytical Services and Quality
  • Enabling Services
Home/End-to-End Capabilities/Process Development

Process Development

Redefining cell and gene therapies through cutting-edge process development.

// End-to-end
   Capabilities

Where the Process is the Product

Our expertise spans the full spectrum of solutions necessary for your genetic medicines. Our deep understanding of the product development needs and extensive technical expertise, combined with our toolbox of platform processes, cutting-edge bioprocessing instruments and high-throughput analytical methods, ensures scalable and robust processes are developed right from the start and allows seamless program transition from early-stage, clinical development through all the way to commercialization.

Industry-Leading Expertise to Accelerate Development

We can partner with you to develop scalable and robust processes for cell therapy and viral vectors to support your clinal and commercial production needs, including adeno-associated viruses (AAV) and lentiviruses based on our proprietary LentiPeak™ lentiviral vector platform.

Process Development

Optimization and Scale-up
Process Characterization
Optimization and Scale-up

Optimization and Scale-up

With a variety of cell therapy and viral vector manufacturing platform processes already established, our dedicated team can quickly develop and optimize your processes based on your desired product profile. Our toolbox of operation procedures offers flexibility across different cell types and products while enabling the customization your product requires.

The technical expertise and tools available at BaseCamp® ensure our processes are developed right from the start and appropriate for your clinical development needs, getting your product to patients faster.

Process Characterization

Process Characterization

In continuous support of your product development lifecycle, our development teams offer process characterization services to gather well-understanding of the critical process performance parameters and define effective process control strategies to ensure successful process validation, product registration and commercial production.

With our extensive state-of-the-art in-house analytical methods, product quality attributes are closely monitored during process characterization studies, so we can achieve the right product profile in every step of the development process.

LentiPeak

Our Customizable LentiPeak™ Platform

Our proprietary lentiviral vector (LVV) platform can be completely customized to meet your specific development needs. LentiPeak™, our suspension-based, scalable lentiviral vector production platform, enables efficient transition for cell and gene therapies from preclinical stage through clinical development and commercialization with accelerated timelines and reduced manufacturing costs.

Learn more

Our Technology Platforms

We gain insights across gene editing, cell therapy, and RNA, protein, and vector technologies to create a virtuous cycle that enable us to iterate and apply best practices across our ecosystem to accelerate and improve the product development process.

Learn about our technology

Our Therapeutic Approaches

Our expansive network of technologies and capabilities enables us to discover, develop, manufacture, and commercialize a broad spectrum of cell and gene therapies.

Learn about our therapeutic designs

What’s New

All News & Pubs

// May 12, 2025

ElevateBio Appoints Ger Brophy, Ph.D., as Interim Chief Executive Officer and Member of the Board of Directors

Read More about ElevateBio Appoints Ger Brophy, Ph.D., as Interim Chief Executive Officer and Member of the Board of Directors

// April 28, 2025

ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Read More about ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Elevated Insights

LETI-101: Life Edit’s Novel Gene Editing Approach to Huntington’s Disease Treatment

By Amy Pooler, Ph.D., SVP, Research and Development of Life Edit

View Insight

Partner with ElevateBio®

Wherever you are in your product lifecycle, we can strengthen and accelerate the development of your transformative therapies with our enabling technologies unmatched manufacturing capabilities.

Work with Us

// Work with us

Footer

ElevateBio

Investors & Media

LinkedIn Twitter

© 2025 ElevateBio. All Rights Reserved.

Privacy & Cookie Policy

  • End-to-End Capabilities
  • Technology Platforms
  • Therapeutic Design & Approaches
  • Partnering
  • About
  • Investors & Media
  • Careers
  • Contact
MENU
  • End-to-End Capabilities
    • End-to-End Capabilities Overview
    • cGMP Manufacturing and Automation
    • Process Development
    • Analytical Services and Quality
    • Next-Generation Sequencing
    • Apheresis
    • Enabling Services
  • Technology Platforms
    • Technology Platforms Overview
    • Gene Editing
    • Cell Therapy Enabling Technologies
    • RNA, Protein & Vector Engineering
  • Therapeutic Design & Approaches
    • Therapeutic Design & Approaches Overview
    • Ex Vivo Cell & Gene Therapies
    • In Vivo Gene Therapies
  • Partnering
    • Partnering Overview
    • Industry Partnerships
    • Academic Partnerships
  • About
    • About Overview
    • Our Story
    • Our Ecosystem
    • Our Team
    • Culture of Expedition
    • Careers
  • Investors & Media
    • Investors & Media Overview
    • Press Releases
    • Posters & Publications
    • Elevated Insights
  • Careers
  • Locations
  • Contact